Comparison of Efficacy of Tranexamic Acid Mesotherapy Versus 0.9% Normal Saline for Melasma
Launched by JINNAH POSTGRADUATE MEDICAL CENTRE · Nov 17, 2019
Trial Information
Current as of June 25, 2025
Completed
Keywords
ClinConnect Summary
In this prospective single blind split face controlled trial.Total 30 patients referred to Dermatology Ward were selected. At first, patients were examined under wood lamp for determination of melasma type (epidermal, dermal). Then, patients underwent Tranexamic acid microinjections with a concentration of TA 4 mg/ml with 0.9 % normal saline on their left half of the face and only 0.9%normal saline on their right half of the face, with mesotherapy technique. This procedure was done total of six times with 2-week intervals. Participants were assessed by Hemi Modified Melasma Area and Severit...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • informed consent
- • age between 18 to 55 years
- • bilateral symmetrical mild to severe melasma
- Exclusion Criteria:
- • pregnancy and lactation
- • history of taken any topical treatment for melasma in previous 1 month
- • history of bleeding disorders
- • concomitant use of anticoagulants,
- • any known drug allergy especially to the study drug,
- • having associated medical illnesses.
About Jinnah Postgraduate Medical Centre
Jinnah Postgraduate Medical Centre (JPMC) is a premier healthcare institution in Pakistan, renowned for its commitment to medical education, research, and high-quality patient care. As a leading clinical trial sponsor, JPMC aims to advance medical knowledge and improve therapeutic outcomes through rigorous clinical research. With a multidisciplinary team of experts and state-of-the-art facilities, JPMC is dedicated to fostering innovation in healthcare by conducting ethically sound and scientifically robust clinical trials, contributing to the global body of medical research while prioritizing patient safety and well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Karachi, Sindh, Pakistan
Patients applied
Trial Officials
rabia ghafoor, FCPS
Study Director
Assistant Profesor
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials